Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Risk Stratification to Predict Renal Survival in Anti-Glomerular Basement Membrane Disease

L. Floyd, S. Bate, A. Hadi Kafagi, N. Brown, J. Scott, M. Srikantharajah, M. Myslivecek, G. Reid, F. Aqeel, D. Frausova, M. Kollar, PL. Kieu, B. Khurshid, CD. Pusey, A. Dhaygude, V. Tesar, S. McAdoo, MA. Little, D. Geetha, SR. Brix

. 2023 ; 34 (3) : 505-514. [pub] 20221129

Jazyk angličtina Země Spojené státy americké

Typ dokumentu multicentrická studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004035
E-zdroje Online Plný text

NLK Free Medical Journals od 1990 do Před 1 rokem
PubMed Central od 2008 do Před 1 rokem
Europe PubMed Central od 2008 do Před 1 rokem
Open Access Digital Library od 1990-07-01

Odkazy

PubMed 36446430
DOI 10.1681/asn.2022050581
Knihovny.cz E-zdroje

SIGNIFICANCE STATEMENT: Most patients with anti-glomerular basement membrane (GBM) disease present with rapidly progressive glomerulonephritis, and more than half develop ESKD. Currently, no tools are available to aid in the prognostication or management of this rare disease. In one of the largest assembled cohorts of patients with anti-GBM disease (with 174 patients included in the final analysis), the authors demonstrated that the renal risk score for ANCA-associated vasculitis is transferable to anti-GBM disease and the renal histology is strongly predictive of renal survival and recovery. Stratifying patients according to the percentage of normal glomeruli in the kidney biopsy and the need for RRT at the time of diagnosis improves outcome prediction. Such stratification may assist in the management of anti-GBM disease. BACKGROUND: Prospective randomized trials investigating treatments and outcomes in anti-glomerular basement membrane (anti-GBM) disease are sparse, and validated tools to aid prognostication or management are lacking. METHODS: In a retrospective, multicenter, international cohort study, we investigated clinical and histologic parameters predicting kidney outcome and sought to identify patients who benefit from rescue immunosuppressive therapy. We also explored applying the concept of the renal risk score (RRS), currently used to predict renal outcomes in ANCA-associated vasculitis, to anti-GBM disease. RESULTS: The final analysis included 174 patients (out of a total of 191). Using Cox and Kaplan-Meier methods, we found that the RRS was a strong predictor for ESKD. The 36-month renal survival was 100%, 62.4%, and 20.7% in the low-risk, moderate-risk, and high-risk groups, respectively. The need for renal replacement therapy (RRT) at diagnosis and the percentage of normal glomeruli in the biopsy were independent predictors of ESKD. The best predictor for renal recovery was the percentage of normal glomeruli, with a cut point of 10% normal glomeruli providing good stratification. A model with the predictors RRT and normal glomeruli ( N ) achieved superior discrimination for significant differences in renal survival. Dividing patients into four risk groups led to a 36-month renal survival of 96.4% (no RRT, N ≥10%), 74.0% (no RRT, N <10%), 42.3% (RRT, N ≥10%), and 14.1% (RRT, N <10%), respectively. CONCLUSIONS: These findings demonstrate that the RRS concept is transferrable to anti-GBM disease. Stratifying patients according to the need for RRT at diagnosis and renal histology improves prediction, highlighting the importance of normal glomeruli. Such stratification may assist in the management of anti-GBM disease. PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2023_02_27_JASN0000000000000060.mp3.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004035
003      
CZ-PrNML
005      
20241119084402.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1681/ASN.2022050581 $2 doi
035    __
$a (PubMed)36446430
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Floyd, Lauren $u Division of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester, United Kingdom $u Renal Department, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, United Kingdom
245    10
$a Risk Stratification to Predict Renal Survival in Anti-Glomerular Basement Membrane Disease / $c L. Floyd, S. Bate, A. Hadi Kafagi, N. Brown, J. Scott, M. Srikantharajah, M. Myslivecek, G. Reid, F. Aqeel, D. Frausova, M. Kollar, PL. Kieu, B. Khurshid, CD. Pusey, A. Dhaygude, V. Tesar, S. McAdoo, MA. Little, D. Geetha, SR. Brix
520    9_
$a SIGNIFICANCE STATEMENT: Most patients with anti-glomerular basement membrane (GBM) disease present with rapidly progressive glomerulonephritis, and more than half develop ESKD. Currently, no tools are available to aid in the prognostication or management of this rare disease. In one of the largest assembled cohorts of patients with anti-GBM disease (with 174 patients included in the final analysis), the authors demonstrated that the renal risk score for ANCA-associated vasculitis is transferable to anti-GBM disease and the renal histology is strongly predictive of renal survival and recovery. Stratifying patients according to the percentage of normal glomeruli in the kidney biopsy and the need for RRT at the time of diagnosis improves outcome prediction. Such stratification may assist in the management of anti-GBM disease. BACKGROUND: Prospective randomized trials investigating treatments and outcomes in anti-glomerular basement membrane (anti-GBM) disease are sparse, and validated tools to aid prognostication or management are lacking. METHODS: In a retrospective, multicenter, international cohort study, we investigated clinical and histologic parameters predicting kidney outcome and sought to identify patients who benefit from rescue immunosuppressive therapy. We also explored applying the concept of the renal risk score (RRS), currently used to predict renal outcomes in ANCA-associated vasculitis, to anti-GBM disease. RESULTS: The final analysis included 174 patients (out of a total of 191). Using Cox and Kaplan-Meier methods, we found that the RRS was a strong predictor for ESKD. The 36-month renal survival was 100%, 62.4%, and 20.7% in the low-risk, moderate-risk, and high-risk groups, respectively. The need for renal replacement therapy (RRT) at diagnosis and the percentage of normal glomeruli in the biopsy were independent predictors of ESKD. The best predictor for renal recovery was the percentage of normal glomeruli, with a cut point of 10% normal glomeruli providing good stratification. A model with the predictors RRT and normal glomeruli ( N ) achieved superior discrimination for significant differences in renal survival. Dividing patients into four risk groups led to a 36-month renal survival of 96.4% (no RRT, N ≥10%), 74.0% (no RRT, N <10%), 42.3% (RRT, N ≥10%), and 14.1% (RRT, N <10%), respectively. CONCLUSIONS: These findings demonstrate that the RRS concept is transferrable to anti-GBM disease. Stratifying patients according to the need for RRT at diagnosis and renal histology improves prediction, highlighting the importance of normal glomeruli. Such stratification may assist in the management of anti-GBM disease. PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2023_02_27_JASN0000000000000060.mp3.
650    _2
$a lidé $7 D006801
650    12
$a antirenální glomerulonefritida $7 D019867
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a kohortové studie $7 D015331
650    _2
$a prospektivní studie $7 D011446
650    _2
$a ledviny $7 D007668
650    _2
$a náhrada funkce ledvin $7 D017582
650    _2
$a hodnocení rizik $7 D018570
650    12
$a ANCA-asociované vaskulitidy $7 D056648
655    _2
$a multicentrická studie $7 D016448
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bate, Sebastian $u Centre for Biostatistics, Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester, United Kingdom $u Manchester Academic Health Science Centre, Research and Innovation, Manchester University NHS Foundation Trust, Manchester, United Kingdom
700    1_
$a Hadi Kafagi, Abdul $u Division of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester, United Kingdom
700    1_
$a Brown, Nina $u Division of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester, United Kingdom $u Renal Department, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom
700    1_
$a Scott, Jennifer $u Trinity Health Kidney Centre, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland $u Irish Centre for Vascular Biology, Dublin, Ireland
700    1_
$a Srikantharajah, Mukunthan $u Department of Immunology and Inflammation, Imperial College London, London, United Kingdom
700    1_
$a Myslivecek, Marek $u First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Nephrology, General University Hospital, Prague, Czech Republic
700    1_
$a Reid, Graeme $u Renal Pathology, Adult Histopathology Unit, Manchester University NHS Foundation Trust, Manchester, United Kingdom
700    1_
$a Aqeel, Faten $u Department of Medicine, John Hopkins University, Baltimore, Maryland
700    1_
$a Frausová, Doubravka $u First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Nephrology, General University Hospital, Prague, Czech Republic $7 xx0324610
700    1_
$a Kollar, Marek $u Centre of Clinical and Transplant Pathology, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Kieu, Phuong Le $u Division of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester, United Kingdom
700    1_
$a Khurshid, Bilal $u Renal Department, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom
700    1_
$a Pusey, Charles D $u Department of Immunology and Inflammation, Imperial College London, London, United Kingdom
700    1_
$a Dhaygude, Ajay $u Renal Department, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, United Kingdom
700    1_
$a Tesar, Vladimir $u First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Nephrology, General University Hospital, Prague, Czech Republic
700    1_
$a McAdoo, Stephen $u Department of Immunology and Inflammation, Imperial College London, London, United Kingdom
700    1_
$a Little, Mark A $u Trinity Health Kidney Centre, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland $u Irish Centre for Vascular Biology, Dublin, Ireland
700    1_
$a Geetha, Duvuru $u Department of Medicine, John Hopkins University, Baltimore, Maryland
700    1_
$a Brix, Silke R $u Division of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester, United Kingdom $u Renal, Urology and Transplantation Unit, Manchester University NHS Foundation Trust, Manchester, United Kingdom
773    0_
$w MED00002977 $t Journal of the American Society of Nephrology $x 1533-3450 $g Roč. 34, č. 3 (2023), s. 505-514
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36446430 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20241119084358 $b ABA008
999    __
$a ok $b bmc $g 1924598 $s 1190244
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 34 $c 3 $d 505-514 $e 20221129 $i 1533-3450 $m Journal of the American Society of Nephrology $n J Am Soc Nephrol $x MED00002977
LZP    __
$a Pubmed-20230418
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace